• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病例报告:青少年皮肌炎伴严重中枢神经系统受累

Case report: severe central nervous system involvement in juvenile dermatomyositis.

作者信息

Elst Elisabeth F, Kamphuis Sylvia S M, Prakken Berent J, Wulffraat Nicolas M, van der Net Janjaap, Peters A C Boudewyn, Kuis Wietse

机构信息

Department of Pediatric Immunology, University Medical Center of Utrecht, Wilhelmina Children's Hospital, mailbox KC.03.063.0, 3508 AB Utrecht, The Netherlands.

出版信息

J Rheumatol. 2003 Sep;30(9):2059-63.

PMID:12966616
Abstract

We present 3 patients with juvenile dermatomyositis (JDM) and severe central nervous system (CNS) complications. All patients had at least 4 positive criteria of Bohan and Peter, which confirmed a definite diagnosis of JDM. They were all male, and had a relatively high creatinine kinase value at admission (1532-4260 U/l). Besides, progressive proximal muscle weakness and rash, one patient presented with rapid irreversible decline of vision. Ophthalmologic examination showed active vasculitis of the retina. After 2 weeks of treatment with immunosuppressive drugs and being in improved, relatively stable clinical condition, all 3 patients developed generalized tonic-clonic convulsions. Other causes of the neurological symptoms could be excluded. In all 3 patients, the course of JDM was fatal. The clinical symptoms and further investigations in our patients show CNS involvement in JDM. Although rarely reported, CNS vasculopathy can be a serious and life-threatening complication of JDM.

摘要

我们报告3例青少年皮肌炎(JDM)并伴有严重中枢神经系统(CNS)并发症的患者。所有患者均至少符合博汉和彼得标准中的4项阳性标准,从而确诊为JDM。他们均为男性,入院时肌酸激酶值相对较高(1532 - 4260 U/l)。此外,除了进行性近端肌无力和皮疹外,1例患者出现视力迅速不可逆下降。眼科检查显示视网膜有活动性血管炎。在接受免疫抑制药物治疗2周且临床状况有所改善并相对稳定后,所有3例患者均出现全身强直阵挛性惊厥。可排除神经症状的其他病因。所有3例患者的JDM病程均为致命性。我们患者的临床症状及进一步检查显示JDM存在中枢神经系统受累。尽管报道较少,但中枢神经系统血管病变可能是JDM的一种严重且危及生命的并发症。

相似文献

1
Case report: severe central nervous system involvement in juvenile dermatomyositis.病例报告:青少年皮肌炎伴严重中枢神经系统受累
J Rheumatol. 2003 Sep;30(9):2059-63.
2
A rare complication of generalized edema in juvenile dermatomyositis: a report of one case.幼年皮肌炎全身水肿的一种罕见并发症:一例报告
Brain Dev. 2004 Jun;26(4):269-72. doi: 10.1016/S0387-7604(03)00171-2.
3
The arthritis of inflammatory childhood myositis syndromes.儿童炎性肌病综合征的关节炎
J Rheumatol. 2001 Jan;28(1):192-7.
4
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap.青少年皮肌炎及青少年皮肌炎-硬皮病重叠综合征患儿的HLA II类单倍型与自身抗体的关联
Rheumatology (Oxford). 2007 Dec;46(12):1786-91. doi: 10.1093/rheumatology/kem265. Epub 2007 Nov 14.
5
An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM).一项关于青少年皮肌炎(JDM)诊断标准的国际共识调查。
Rheumatology (Oxford). 2006 Aug;45(8):990-3. doi: 10.1093/rheumatology/kel025. Epub 2006 Feb 8.
6
Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.幼年皮肌炎大腿肌肉MRI T2弛豫时间的定量评估
Rheumatology (Oxford). 2004 May;43(5):603-8. doi: 10.1093/rheumatology/keh130. Epub 2004 Feb 24.
7
[Juvenile dermatomyositis].[青少年皮肌炎]
Pediatr Med Chir. 1990 Nov-Dec;12(6):587-91.
8
Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores.青少年皮肌炎(JDM)中的口咽吞咽困难:一项关于电视荧光吞咽造影检查(VFSS)变化与临床症状及客观肌肉评分关系的评估
Rheumatology (Oxford). 2007 Aug;46(8):1363-6. doi: 10.1093/rheumatology/kem131. Epub 2007 Jun 14.
9
[Juvenile dermatomyositis].
Reumatizam. 2001;48(1):27-33.
10
Clinical features and disease course of patients with juvenile dermatomyositis.青少年皮肌炎患者的临床特征和疾病过程。
Int J Rheum Dis. 2013 Oct;16(5):561-7. doi: 10.1111/1756-185X.12107. Epub 2013 Jun 3.

引用本文的文献

1
Dermatomyositis-Related Encephalopathy: Clinical, Neuroimaging and Immunological Characterization.皮肌炎相关脑病:临床、神经影像学及免疫学特征
Diagnostics (Basel). 2025 Mar 12;15(6):700. doi: 10.3390/diagnostics15060700.
2
Juvenile dermatomyositis with central nervous system involvement: two case reports from a retrospective single-center cohort, with literature review.伴有中枢神经系统受累的青少年皮肌炎:一项回顾性单中心队列研究中的两例病例报告及文献综述
Front Pediatr. 2024 May 30;12:1409950. doi: 10.3389/fped.2024.1409950. eCollection 2024.
3
Diagnosis of neuropsychiatry disorder in patients with anti-MDA5 antibody dermatomyositis: A case report.
抗MDA5抗体皮肌炎患者神经精神障碍的诊断:一例报告
Heliyon. 2023 Nov 28;9(12):e22935. doi: 10.1016/j.heliyon.2023.e22935. eCollection 2023 Dec.
4
Childhood Cerebral Vasculitis : A Multidisciplinary Approach.儿童脑血管炎:多学科方法。
Clin Neuroradiol. 2023 Mar;33(1):5-20. doi: 10.1007/s00062-022-01185-8. Epub 2022 Jun 24.
5
Antimelanoma differentiation-associated gene 5 dermatomyositis associated with acute encephalopathy.抗黑色素瘤分化相关基因5皮肌炎伴急性脑病
JAAD Case Rep. 2021 Apr 28;13:20-22. doi: 10.1016/j.jdcr.2021.04.017. eCollection 2021 Jul.
6
Epilepsy as a Comorbidity in Polymyositis and Dermatomyositis-A Cross-Sectional Study.多发性肌炎和皮肌炎合并癫痫:一项横断面研究。
Int J Environ Res Public Health. 2021 Apr 10;18(8):3983. doi: 10.3390/ijerph18083983.
7
Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.在幼年特发性肌炎中使用 IVIG 或环磷酰胺进行挽救性治疗。
Curr Rheumatol Rep. 2021 Mar 8;23(4):24. doi: 10.1007/s11926-021-00990-3.
8
Treatment of Calcinosis in Juvenile Dermatomyositis.治疗幼年皮肌炎的钙质沉着症。
Curr Rheumatol Rep. 2021 Feb 8;23(2):13. doi: 10.1007/s11926-020-00974-9.
9
CNS Vasculitis in Anti-Synthetase Syndrome.抗合成酶综合征中的中枢神经系统血管炎
Mediterr J Rheumatol. 2020 Mar 31;30(4):220-223. doi: 10.31138/mjr.30.4.220. eCollection 2019 Dec.
10
Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.幼年皮肌炎:临床表现、肌炎特异性抗体及治疗方面的进展
World J Pediatr. 2020 Feb;16(1):31-43. doi: 10.1007/s12519-019-00313-8. Epub 2019 Sep 26.